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Abstract
Infectious diseases and septicemia are two of the major causes of death in the U.S.,
necessitating rapid treatment of septic patients with proper, efficacious antibiotics.
Unfortunately, the emergence and spread of multidrug-resistant bacteria are continuously being
aggravated by an abuse in antibiotic prescription at a clinical and agricultural level. It is known
that antibiotic resistance evolves through the sequential accumulation of multiple mutations in
bacteria, which is accentuated by prolonged exposure of bacteria to ineffective antibiotics when
implementing traditional septicemia treatment. The goal of this project is to develop a novel,
easy-to-use AST platform for rapid antimicrobial susceptibility profiling to reduce the incidence
and mortality rates, and to reduce inappropriate antibiotic usage commonly associated with
invasive pathogens. As time progresses, antibiotic resistance becomes more prevalent and so
does the need to effectively test antibiotics on any given bacteria strain in a timely manner. This
project will utilize an E. coli bacteria and antibiotic plating method combined with a single-celllevel lensless imaging system to achieve this task. Here we propose a device that incorporates
the working principle of a speckle-scanning pictographic lensless imaging scheme to visualize
(in real-time) the growth of single cells of bacteria in a microscopic population under different
antibiotic types and different concentrations of respective antibiotics. This system may further be
optimized by directly imaging a blood sample, effectively bypassing the time it takes to perform
traditional blood sampling, culture isolation, and culture propagation for antibiotic susceptibility
testing. Our model organism will be Escherichia coli K-12 - a gram-negative facultative
anaerobe with a generation time of 20-30 minutes.

Introduction
Antibiotic resistance is a major healthcare concern worldwide [1]. Antibiotics are overprescribed and misused, which significantly impacts the effectiveness of the drug. With every hour
of delay until a patient is introduced to an antibiotic, their survival rate decreases by 7.6% [2].
Antibiotic susceptibility testing takes time that a patient suffering from infection doesn’t have.
Typically a general antibiotic is administered rather than testing for the most effective strain, which
in many cases can lead to the bacterial microorganisms building a resistance to the drug meant
to remove them.
Antibiotic resistance took around 700,000 people’s lives in 2014 and is projected to grow
greatly [3]. The economic toll associated with increased time spent in hospitals is also expected
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to grow from $35 billion to nearly $100 trillion by 2050[4]. Rapid antibiotic susceptibility testing will
mitigate these effects as the correct antibiotic will be able to be chosen at the start of patient care.
The gold standard for antibiotic susceptibility testing takes 10-36 hours to correctly identify
the best antibiotic to prescribe [5]. In the meantime, patients are typically given a wide array of
antibiotics while they await lab results. We intend to lower the chances of antibiotic resistance by
removing the need to prescribe ineffective antibiotics while awaiting lab results. We will do this by
reducing lab times from 12-36 hours to 1-2 hours. We will develop a platform to test various types
of antibiotics at multiple concentrations and their effect on the proliferation of certain bacteria.
Using a lensless imaging platform we will be able to determine the most effective type and
concentration of antibiotic at a much faster rate.
The proposed project starts with culturing bacterial samples on agar plates and
propagating the cultures. Six concentrations of up to four different antibiotics will be introduced to
separate chambers (for a total of 24 chambers). Alternatively, the testing platform may consist of
two channels - one for water and one for a concentrated antibiotic solution. The channels will be
connected to a middle agar channel, allowing for the establishment of a concentration gradient of
a single antibiotic (this unit is to be repeated four times for four types of antibiotics). The growth
of bacteria in response to the antibiotic will be observed using a high-resolution lensless imaging
technology that will allow for the observation of single-cell activity, and a comparison of instances
of growth will be used to determine the minimum inhibitory concentration of the sample.

Literature Review
In 1928, scientist Alexander Fleming was crowned with the discovery of a miracle drug Penicillin [6]. This accidental antibiotic discovery has gone on to save millions of lives by
effectively treating diseases and conditions that were once considered life-threatening and fatal.
The versatility of this drug has led to non-specific administration and abuse, ultimately leading to
the accelerated development of antibiotic-resistant bacterial pathogens. The rise of multidrugresistant pathogenic lifeforms has since threatened global health, as propagation of antibiotic
resistance via horizontal transfer (from bacteria-to-bacteria) of plasmids containing drugresistant genes is rapid and often uncontested [6]. In modern-day hospital settings, patients who
show signs of septicemia (acute blood infection) are promptly treated with a “cocktail” of broadrange antibiotics in hopes of inhibiting further damage to the host. Four hours after the delivery
of the initial antibiotic(s), blood samples are collected to be tested for the presence and
identification of microorganisms. Upon positive identification, further extensive tests are required
to identify the antibiotic susceptibility profile of each individual strain present. This common
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protocol can take anywhere from 24 hours to several days, depending on the growth rate and
efficacy of preliminary broad-range antibiotics. This lag time and abuse of broad-range
antibiotics are speculated to increase the chances of the pathogenic strains developing
antibiotic resistance, as bacterial communities grow accustomed to their static environment.
Thus, every hour of delay (or every hour of improper treatment) is estimated to decrease the
survival rate of sepsis by approximately 7.6% [2]. The development of Rapid Antibiotic
Susceptibility Testing systems that incorporate accurate identification with determination of the
minimum inhibitory concentration (MIC) is of high priority. Such a system allows for
simultaneous identification of the pathogen whilst determining efficacious treatment options in a
fraction of the time required for traditional analysis protocols to significantly decrease the
mortality rate of septicemia [5].
Proper treatment of diseased patients and inhibition of the development of antibiotic
resistance requires scientists and clinicians to establish the susceptibility profile of pathogenic
bacteria before treatment with broad-range antibiotics. The rapid identification of a bacterial
susceptibility profile enables accurate treatment with an efficacious antibiotic that prevents the
possibility of bacterial propagation, development of resistance, and horizontal transfer of
plasmids [7]. Under traditional treatment protocols, infectious bacteria are exposed to a constant
drug concentration that partially or completely kills or inhibits the growth of the base strain. This
method, while capable of inhibiting the progress of septic shock, imposes a selective advantage
for drug-resistant mutants under gradual rates of evolution [8]. Phenotypic Antibiotic
Susceptibility Testing (ASTs) are based on the detection of bacterial growth in the presence of
different types of antibiotics, different concentrations of respective antibiotics, and growth on
either a liquid or solid media. Modern-day AST standards (such as broth microdilution) achieve
reliable result readouts in 12-36 hours. However, this significant time delay fails to guide
treatment for the early, critical stages of infection. By the time that a patient is symptomatic, the
pathogen will have already inflicted significant damage on the patient and elicited a major
immune response - not to mention the patient will also begin to display a significant risk to
secondary contacts [7]. The issue arises from the lack of current research. Studies have
suggested mutational trajectories that may result in mutations that enable antibiotic resistance,
but single point mutations are often insufficient for the development of a high level of antibiotic
resistance. Thus, the development of a Rapid Antibiotic Susceptibility Testing system is
beneficial for a clinical setting because it severely restricts the amount of time a bacterial strain
is exposed to constant levels of antibiotics, subsequently limiting the potential for mutation. By
rapidly introducing an efficacious antibiotic to a diseased patient, scientists and clinicians may
3

kill all susceptible strains and dispel the survival of spontaneously occurring mutants [8]. Our
Rapid AST solution rapidly determines growth and inhibitory conditions of organisms with
optimal growth conditions. By integrating multiple exposure sites onto a single plate, the new
proposition may test several antibiotics and different concentrations of respective antibiotics at
once. To further reduce analysis time, we will incorporate the working principle of a specklescanning pictographic lensless imaging scheme to visualize (in real-time) the growth of single
cells of bacteria in a small population. By limiting the population size to a microscopic scale and
comparing relative rates of cell division, we hope to capture every instance of cell growth in a
limited time frame. These instances may then be compared to other exposure sites to compare
relative growth rates and determine optimal inhibitory conditions. An ultimate reduction of
diagnostic time would further incorporate direct blood testing to skip over preliminary blood
sampling and culturing while monitoring for bactericidal effects as opposed to bacteriostatic
effects, as the former mechanism ensures elimination of the pathogenic agent whilst the latter
mechanism prevents growth and does not prevent conjugation.
Currently, there are many methods used for AST including automated and manual
systems. The AST methods that are presently practiced, “in the clinical microbiology labs are
accurate, but are either labor-intensive or time-consuming, leading to long wait times to obtain
AST results” [5, 9, 13, 14]. The problem with these methods is that they all require a lengthy
amount of time to provide results. Current AST manual systems include but are not limited to;
the Broth microdilution method, the agar dilution method, the disk diffusion method, and Etest.
The Current AST automated systems are VITEK, Sensititre, and BD phoenix. Even though both
the manual and automated systems for rapid AST use bacterial growth or metabolism to
determine the effect of antibiotics, automated systems still take the same time as manual
systems to obtain antibiotic susceptibility profiles, “since they require pure bacterial isolates and
use optical methods for interpretation of results” [5, 10, 12, 14, 18]. Today, many clinical
laboratories have switched from manual systems to automated systems as they are easier to
use, don’t require any labor, and have a more effective workflow. Both manual and automated
systems have their advantages and disadvantages, and their common disadvantage is time.
Two qualities of rapid AST are accuracy and time, with accuracy being efficient, the amount of
time to produce results is not. This is due to current technologies require either pure cultural
isolates or use observation of changes to bacterial metabolism. The main focus of emerging and
future methods is to reduce the time as much as possible by having the same working accuracy
for results. Researchers are now going after rapid AST systems that can bypass the need for
pure isolate, use patient samples directly, and improve the sample processing time. With the
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abilities of these characteristics, the future of patient treatment can be attained, the use of broad
antibiotics can be reduced, and AST outcomes can prosper.
Table 1: Summary of the state of antibiotic susceptibility testing platforms [5].
System

Approach

Time for AST

Broth Microdilution
(Golden Standard)

Media containing different antibiotics tested against
the pathogen of interest

24-36 hours

Agar Dilution

Antibiotic incorporated directly into agar plates,
bacteria inoculated on the surface. Multiple plates
may be concocted sequentially and incubated
simultaneously.

16-24 hours

Disk Diffusion

Antibiotic-impregnated filter discs placed on agar
surface pre-inoculated with pathogen

16-36 hours

Etest

Plastic strip impregnated with gradually decreasing
concentrations of antibiotics placed on agar surface
pre-inoculated with pathogen

24-36 hours

VITEK System

Measures light attenuation by optical scanners for
growth/no growth detection in micro-wells with
different antibiotics

12-36 hours

Sensititre

Fluorescence technology used to monitor the activity
of enzymes produced by test organism emitting
fluorescence

12-24 hours

BacterioScan FLLS

Uses laser light source with scattered intensity
measurements for accurate Optical Density readings
in the presence of antibiotics

10-24 hours

BD Pheonix
Automated ID and
AST

Automated broth microdilution that uses a redox
indicator to detect growth, capable of reading 99
panels at once

4-16 hours

Micro-scan Walk
Away

Colorimetric readings based on photosensors for
optical detection of bacteria in 40-96 panels

4.5-7 hours (up

MALDI-TOF Mass
Spectrometry

Culture inoculated into different suspensions
containing antibiotics, and growth rate is calculated
from spectra

3-5 hours

(per plate)

to 18 hours)
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Agonistic RealTime PCR

Isolates propagated on agar or broth with antibiotics,
and PCR run to determine inhibition of growth

2-4 hours

Our System

Ptychographic lensless imaging over a large field
of view. Determines growth or no growth at
single-cell resolution level of multiple panels at
once

30min-2 hours

Broth Dilution Methods
Current broth macro- and microdilution methods utilize multiple panels (wells), each filled
with a range of antibiotics at different concentrations. These methods require that the bacteria of
interest be isolated, grown on agar plates, and suspended in media. An equal amount of the
inoculated media is introduced into all wells except for the positive and negative controls.
Following an incubation period of 6-24 hours (or more), the wells are observed for signs of
growth. This application may be extended to agar plate applications. In this case, antibiotics are
directly incorporated into respective liquid agar samples, which are then poured into respective
plates. After the agar has set, bacteria is directly inoculated onto the surface and the plate is
incubated and checked for growth [5, 13].

Diffusion Methods
Antibiotic susceptibility testing methods that utilize diffusion of antibiotics include Disk
Diffusion and Etests. In both of these tests, a bacterial sample isolated from the patient is
directly swabbed onto a sterile agar plate. The Disk Diffusion method utilizes a series of
predetermined concentrations of antibiotic-laden discs (of filter paper). These antibiotic-laden
discs are placed onto the surface of the agar, and the plate is allowed to incubate for up to 24
hours. Following this, the diameter of the zones of inhibition around the discs are recorded to
determine the efficacy of the tested antibiotics against the bacterial sample [5, 11, 13].
The Etest method utilizes the diffusion mechanism of the Disk Diffusion method. In
contrast, Etests utilize impermeable plastic strips impregnated with a gradient of a given
antibiotic (from high to low concentration). These strips are placed onto the inoculated agar, and
the plate is incubated for up to 24 hours. The growth patterns may then be used to determine
the minimal inhibitory concentration of an antibiotic, determined as the minimum concentration
on the Etest at which bacterial growth is inhibited [5].
Automated Methods
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The VITEK System, Sentititre Plate, BacterioScan FLLS, BD Pheonix Automated ID and
AST, Micro-Scan Walk-Away, and MALDI-TOF systems are all based on the Broth
Microdilution. These systems utilize scanners to measure light attenuation, fluorescence,
indicators, or mass spectrometry to determine optical density as a factor of growth rate. Given
the sensitivity of scanners over human vision, these systems advertise significantly decreased
times required to compile a bacterial sample’s antibiotic susceptibility profile [5, 9, 10, 11, 12,
13, 14, 15, 16].
However, scanning systems rely on reasonably large changes in the existing bacterial
population to determine the antibiotic susceptibility profile. While they address issues associated
with incubation and imaging, they do not address delays associated with pre-AST stages
(clinical sampling, bacterial isolation, etc.). We are seeking to design a low-cost, rapid antibiotic
susceptibility testing platform that enables active imaging of individual bacterial cells under a
wide field-of-view [7, 19]. By monitoring singular instances of fission in bacterial cells subjected
to select antibiotics under a concentration gradient, we hope to drastically reduce the time of
antibiotic susceptibility profiling down to the generation time of a given bacterial species.
Furthermore, we hope to extrapolate this design and utilize raw clinical blood samples to further
decrease the time required for AST. Given the complexity and cost associated with automated
systems, it was determined that these methods would be outside the realm and budget of this
design.

Materials and Methods
Needs Analysis & Function Specifications
The final goal of this design is to successfully integrate with a single-cell-level lensless
imaging system that is capable of tracking bacterial fission in a large population of cells (ideally
>50). We are creating a platform to appropriately test the effect of various concentrations of
antibiotics on bacteria. This culture will then be imaged by a predetermined device, therefore
compatibility is key. Biosafety level is ranked the lowest. It was made clear due to lab resources
that a Biosafety Level 1 is ideal (with up to Biosafety Level 2 available), but this does not hold
more weight than the other specified needs. Finally, for this device to be applicable to the rapid
AST market, it must be portable for ease of use in medical settings. A portable model assumes
an efficient and ergonomic design, and the capacity to utilize multiple platforms in rapid
succession.
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Table 2: Functions (Specifications)
Function

Specification

Allow for viewing access

Use of clear PDMS for platform and agar
growth medium on top of the device for
straight forward imaging

Test for multiple antibiotics

Use of 2-3 different types of antibiotics

Allows for a linear concentration gradient

Two regions connected by a channel
allow for linear diffusion of antibiotics into
an aqueous buffer

Allows for direct access

Ability to add antibiotic and draw samples
at any time while experimenting

Allows for material interaction

Allow bacteria and antibiotic to interact

Propagates growth of bacteria

Agar channel allows for surface growth
and adhesion of E.coli

Prevents adhesion

Prevent adhesion of the antibiotics and
bacteria to the surface of the device

Can be easily manufactured

Low cost of the 3D printed mold, high
quantity of PDMS available, and relatively
high curing rate of PDMS allows for many
devices to be fabricated

Concept
The task at hand was to create a petri-dish-like assembly that could allow for a
comparison of how various concentrations of different types of antibiotics affect bacterial growth.
The main issue we faced was the need to identify which concentration of antibiotic was affecting
specific areas of the bacteria culture as a means to determine the minimum inhibitory
concentration of an antibiotic on a particular strain of bacteria (in this case, E. coli). It was
decided that the need for different concentrations throughout the culture can be solved by
establishing a concentration gradient via linear diffusion of antibiotics into an aqueous buffer.
This eliminates the need for complete sectioning of the culture and a clustered multi-well
configuration. The meeting concluded with the decision to diffuse water and antibiotics from two
wells placed on opposite ends of the bacterial culture (agar) and base the applied
8

concentrations off distance from the source (via linear diffusion approximation). The hope is that
the antibiotic concentration is the strongest when it is closest to the antibiotic well and linearly
dilutes into a negligible concentration near the well filled with a buffer solution. The design is still
in the early stages and it is unclear how exact concentrations will be calculated after diffusion.
The design created is shown in Figures 1-2.
The initial design considered was to print molds of a microfluidic box. Using the below
diagrams (Figures 1-2), Part A was to be placed on top of Part B, and a PDMS solution poured
through the holes in the top. After proper gelling and curing of the solution, a nutrient agar
solution inoculated with bacteria would be poured through the top, and the resulting product
would be a device that could accurately demonstrate bacteria growth and susceptibility to
various antibiotics. As agar media is porous, bacteria would be capable of evenly growing over
the surface of the agar platform. However, a few issues arose with this initial design. Primarily,
Part A contains a hole in the center, which was initially designed to allow for removal of the part
after solidification of both PDMS and agar. However, this would cause a large number of issues.
The hole is not large enough to encompass all of the agar, so a significant amount would be
displaced during this process. Additionally, the sides of the center wall, when removed, would
cause leakage between the two wells. Finally, Part B doesn’t allow easy removal of the entire
system - it would be hard to separate the PDMS base from the mold base. Therefore, the next
design needed three main improvements.
1. Easier removal of Part A from agar
2. No gap between agar and PDMS
3. Easier removal of PDMS from Part B

Figure 1: Conceptual Design of Microfluidic Box Top - PDMS
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Figure 2: Conceptual Design of Microfluidic Box Base

Preliminary Design
It was originally intended that the device be composed of several microfluidic channels that
integrated the same antibiotic-buffer concentration gradient. However, this design was ruled out
as the method in which bacteria were to be imaged required for the formulation of fluid channels
capable of housing single bacterium cells. This would lead to difficulty due to the macroscopic
resolution of any available printing device, the varied morphology of bacterial cells, and the
difficulty imagining growth rate in small populations. At any given time, a small subset of
bacterial cells are in the process of active binary fission (replication), and the incidence of
bacterial division may be increased by increasing our sample size (the bacterial population)
from a single cell to several colony-forming units (CFUs). The issues that were found in the
initial box design were resolved by remodeling. The new design is pictured in Figures 3-5.
Improvement 1 needed an easier removal of Part A from the PDMS. This is addressed by
removing the hole from the center of Part A, and the addition of Part C. Now, Part A will only be
used for the gelling of PDMS. Once the PDMS has solidified, Part A will be removed and Part C
will take its place. The agar solution will be poured through the center of Part C and removed
once the agar solidifies. This system also remediates Improvement 2 - there will no longer be a
gap between the agar and PDMS due to the thin mold wall. The final improvement in this design
is the removal of the bottom of Part B. The product can be made on a flat surface such as in a
Petri dish. After solidification, the product can be removed by sliding a knife around the interior
walls of the box base.
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Figure 3: Initial Design of Microfluidic Box Top - PDMS

Figure 4: Initial Design of Microfluidic Box Base

Figure 5: Initial Design of Microfluidic Box Top - Agar
11

A growth-oriented alternative design utilized direct blood samples from patients to create
the agar platform on which bacteria are to be cultured and tested for antibiotic susceptibility. The
theory behind this design utilizes the concept of 5-10% mammalian blood-enriched agar plates,
currently used in microbiology laboratory settings as a means to cultivate bacteria that are both
simple and fastidious, as well as differentiate the bacterial colonies based on hemolytic
properties. It is known that blood cultures isolated from patients take approximately 12 to 72
hours to yield positive results for identification and antibiotic susceptibility testing protocols [5, 9,
10, 11, 13, 17]. It is theorized that by directly introducing patient blood samples to a broth-agar
media (e.g. melted tryptic soy agar) and pouring a very thin layer of the agar onto the
microfluidic device, there would be little to no need for preliminary incubation of the bacterial
samples. The bacteria initially present in the blood will now be present within the solidifying thinagar platform and is free to grow on the surface. As the amount of agar to be used in each
microfluidic well is minimal, one blood sample may be used to test multiple antibiotics and
multiple concentrations of respective antibiotics. We consulted Professor Joerg Graf, Professor
and Associate Department Head for Graduate Research and Education in Molecular and Cell
Biology, who told us that the design was entirely feasible for septic patients (albeit the best
method would utilize metabolic dyes, which would likely be outside of the realm of our budget).
By directly introducing patient blood samples to the microfluidic antibiotic susceptibility testing
device, we hope to eliminate preliminary blood testing and ultimately reduce the antibiotic
testing time so that it is equal to the generation time of common bacterial species (e.g. 20-30
minutes for E. coli).
However, a few issues arose with this alternative design. According to Professor Joerg
Graf, bacteria (especially fastidious strains) grow slower in the presence of blood than they
would normally grow in the presence of standard nutrient broths/agars due to the presence of
cytokines and immune cells. Additionally, the lensless pictographic imaging system that will be
utilized, while capable of detecting color, will have great difficulty differentiating bacterial cells
from blood culture cells (erythrocytes, platelets, lymphocytes, etc.) due to the small size of the
bacterial cells (0.2-2.0μm) in relation to erythrocytes (4-10μm) and lymphocytes (7-20μm). It is
possible that an overabundance of erythrocytes and lymphocytes in the agar will prevent an
accurate assessment of bacterial concentrations and bacterial growth, even if the imaging
system is capable of capturing cross-sectional images. Ultimately, this alternative design is
limited by the number of bacterial cells present in the blood sample of a patient who is septic. At
the onset of clinical symptoms of sepsis, the concentration of bacteria in a blood sample is very
12

low (1-300 CFU/mL), so it is highly recommended that the blood sample undergo preliminary
subculturing and biochemical identification before antibiotic susceptibility testing protocols [5].
Alternative Designs
The primary component in the creation of the rapid antibiotic susceptibility test is the
platform on which the bacterial sample would be cultured and exposed to antibiotics. When the
rapid assessment of antibiotic susceptibility profiles was factored into the design, it was
determined that the conceptual anaerobic incubation conditions were not optimal for the goal of
this project. Additionally, the conceptual design could not be moved during the testing process
to avoid disequilibrium of the diffusion gradient and bacterial population. To integrate our device
with a higher-level imaging system, the antibiotic effectiveness would need to be modeled on a
microfluidic assembly that is minimally obstructive and can be moved freely during any stage of
testing.
Thus, a new preliminary design was modeled off of the popular “Etest” antibiotic
susceptibility testing system. The new AST device consisted of three independent wells
connected with a porous strip that would establish the antibiotic gradient. This connecting strip
enables the diffusion and the establishment of an antibiotic gradient over the middle culturing
(agar) well by inserting itself into both end wells (antibiotic solution and distilled water,
respectively). As the strip would possess a significantly smaller cross-sectional area than the
conceptual channel-design, the preliminary device would be able to reduce the impact that
kinetic disequilibria would have on the diffusion gradient by minimizing the flow of liquids.
The box design is pictured in Figures 6 and 7. This box will be used as a mold for a
Polydimethylsiloxane (PDMS) solution. Part A will only be used for the gelling of PDMS. Once
the PDMS has solidified, Part A will be removed and Part C taking its place. The agar solution
will be poured through the center of Part C and removed once the agar solidifies. After
solidification of PDMS, the product can be removed by sliding a knife around the interior walls of
the box base.

Figure 6: Preliminary Design of Microfluidic Box Top
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Figure 7: Preliminary Design of Microfluidic Box Base
Preliminary prototyping using the 3D printers and resin printer determined that the
minimum resolution that may be obtained will not be small enough to house single bacterial
cells (typically 0.2-0.4um). As a result of this, a microfluidic channel that visualizes the growth of
small populations (<5) of bacterial cells should not be utilized, and we opted for a design that
favored significant bacterial populations (ideally >50 cells). It was also determined that a
metabolic fluorescence compound or a live-dead strain of active bacterial cells would be the
absolute fastest way to determine an antibiotic’s minimum inhibitory concentration, as we would
simply test for active enzymatic activity (5-10 minutes) as opposed to testing for binary fission in
bacteria (30min - 8 hours). While the provided lensless pictographic imaging system is capable
of detecting colors, this method was later found to cost several hundred, if not thousands, of
dollars to complete a fluorescence analysis.
It was determined that under improper storage conditions (greater than -4℃), bacterial
colony samples were metabolically active and were unable to survive for greater than 3 weeks
without re-isolation and subsequent incubation in fresh nutrient medium. As a result of this
feasibility study, it was determined that the E. coli samples are to be stored in an ultra-low or
cryogenic freezer at conditions of -40 degrees centigrade or less.
Bacterial populations inoculated into a liquid nutrient-agar broth at a temperature of 37
degrees centigrade were capable of growing on the surface and within the nutrient-agar medium
once solidified. This enables the inoculation of patient bacterial samples into a liquid medium
and subsequent introduction and cultivation of bacterial samples directly on the microfluidic
device via the pouring method, as previously mentioned.
Feasibility Study
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Testing of the conceptual (initial) design of the rapid AST prototype with blue dye
determined that kinetic disruption of the device during any phase of testing would result in
disequilibrium of the passive diffusion gradient and ruin the establishment of the antibiotic
concentration gradient (Figures 8 and 9). The generation time of our E. coli bacterial sample
was extended from approximately 25 minutes in controlled aerobic conditions to almost 60
minutes under anaerobic conditions. Thus, the initial design was not utilized as it was poorly
efficacious when considering the goal of rapid AST

Figure 8. Methylene blue dye (light) and distilled water (right well)

Figure 9. Methylene blue dye (light) and distilled water (right well) concentration gradient after
slight disturbance

The preliminary design offered greater flexibility than the initial design, as the porous
strip was able to establish an antibiotic concentration gradient under aerobic growth conditions.
As suspected, the poor resolution of the 3D printer combined with the inverted-mold design
introduced a significant number of microscopic air bubbles into the design. Attempts to remove
these bubbles using low-pressure vacuums failed and the resulting devices were both fragile
and non-functional after one use, as the resultant air pockets penetrated the cured wells (Figure
10).
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Figure 10: Damage of the microfluidic device due to air bubbles

Data and Results
Final Microfluidic Design
To successfully create the mold for the microfluidic box testing platform, the designs
created through SolidWorks must be printed using a 3D printer. There were a few iterations of
this printing due to the need for a mold that was conducive to PDMS solidification. The
resolution of printing and the size of the print were altered for optimal results. Preliminary
prototyping using the 3D printers and resin printer determined that the minimum resolution that
may be obtained will not be small enough to house single bacterial cells, 0.2-0.4um. For initial
testing purposes, the mold was printed in a larger size then the final product would be created
in.
It was thought that the combination of utilizing an inverted-mold design and printing the
device using a 3D printer would introduce microscopic air pockets that would create cavities
during the curing process. As a result, the preliminary design was further optimized and
simplified to eliminate the need to introduce an inverted mold into the uncured PDMS, as seen
in our final optimized mold design (Figure 11).

Figure 11: Final Optimized Design of Microfluidic Box Mold
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The 3-D printed box mold was then used to create the petri-dish like testing platform.
The PDMS was assembled by mixing Sylgard 184 silicone elastomer base and Sylguard 184
silicone elastomer curing agent in a 10:1 ratio in an open container. The open container
containing the mixture was placed under a vacuum for one hour to remove excess air bubbles.
After no air bubbles remain visible, the mixture was poured into the 3D print of the microfluidic
box, and the mold (with the uncured PDMS) was placed into the vacuum for an additional hour.
Afterward, the device was allowed to cure in a 65ºC oven for 6-8 hours. The device was then
removed from the oven, and the PDMS device was removed from the printed mold using
tweezers.
This new optimized design successfully created a prototype of the rapid AST device with
minimal presence of air bubbles. While it was more difficult to remove this device from the mold,
it was determined that the overall integrity, transparency, and efficacy of the final optimized
design far surpassed the conceptual/initial and preliminary designs.

Figure 12. Final optimized mold design (top) and rapid AST device made from solidified PDMS
(bottom)
Preliminary Testing the Prototype:
To simulate an E-test, Luria broth agar was first melted and held at 45 degrees centigrade
to keep the agar in its liquid state. An inoculating loop was used to introduce a small population
of E. coli into a sterile nutrient broth, and the inoculated broth was vortexed to evenly distribute
bacterial cells. 3 mL of the inoculated broth was poured into 10 mL of the liquid agar, and the
resulting inoculated liquid agar was gently vortexed. The liquid agar was rapidly poured into a
sterile petri dish and allowed to set at room temperature. A strip of sterile filter paper was placed
in the middle of the set agar. 4μL of distilled water and 4μL of 5x10-3 μg/μL ampicillin solution
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were introduced to respective ends of the strip simultaneously. The simulated E-test was
incubated at 37⁰C incubator at atmospheric conditions for 18 hours. Figure 13 shows the
simulated E-test, and Figure 14 shows the zone of inhibition at the minimal inhibitory
concentration under a light microscope.

Figure 13: Simulated E-Test using filter paper

Figure 14: Zone of Inhibition at the minimal inhibitory concentration of ampicillin using simulated
E-test (image taken through light microscopy)

Preliminary Results
Using the device, we filled the left and right wells with 5x10-3 μg/μL ampicillin solution
and distilled water, respectively. Sterile Luria broth agar was melted and held at 45 degrees
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centigrade to prevent solidification. A sterile nutrient broth solution was inoculated with a colony
of E. coli, and the inoculated broth was vortexed. 3mL of the inoculated broth was poured into
10mL of the liquid agar, and the resultant inoculated agar was gently vortexed to evenly
distribute bacteria. An initial snapshot of the solidified agar well was taken at 0 minutes, as seen
in Figure 15 (4x magnification) and Figure 16 (10x magnification). The inoculated agar was then
rapidly introduced to the middle well of the device prototype.

Figure 15: Initial snapshot image of the solid inoculated agar taken under light microscopy at 4x
magnification

Figure 16: Initial snapshot image of the solid inoculated agar taken under light microscopy at
10x magnification
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A thin strip of filter paper was placed over one-fourth of the middle well’s agar width, and
the ends of the filter paper were introduced to the liquid wells simultaneously. The device was
incubated in atmospheric conditions at 37⁰C for 8 hours, and a final snapshot of the growth was
documented. The zone of inhibition may be seen in Figure 17 (4x magnification) and Figure 18
(10x magnification). Figure 19 is an image of the zone of inhibition under 20x magnification. At
this magnification, the field-of-view is not wide enough to determine the boundary between
growth and inhibition. Areas that appear dark indicate regions where the bacteria’s growth was
unhindered by the antibiotic concentration. Areas that appear light are similar to the initial
snapshot (t=0) and indicate regions where the antibiotic concentration was high enough to
inhibit growth.

Figure 17: Snapshot image of the solid inoculated agar taken under light microscopy at 4x
magnification after 8 hours of incubation.

Figure 18: Snapshot image of the solid inoculated agar taken under light microscopy at 10x
magnification after 8 hours of incubation.
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Figure 19: Two snapshot images of the solid inoculated agar taken under light microscopy at
20x magnification after 8 hours of incubation. Growth is pictured on the right and inhibition is
pictured on the left.

Discussion
Discussion of the Preliminary Results
The final optimized design of the microfluidic device mold (Figure 11) was able to
produce a relatively transparent and structurally functional device using PDMS (Figure 12). As is
seen with Figures 15-19, the rapid antibiotic susceptibility test device prototype was able to
produce a clear zone of inhibition that represented the minimal inhibitory concentration of an
antibiotic against a population of bacteria. This suggests that our device has the potential to
achieve the goal of rapidly analyzing the antibiotic susceptibility profile of any bacterial sample
under a given antibiotic as the device has proved to be highly efficacious in achieving rapid
AST.
The functioning device was imaged using standard light microscopy at 4x and 10x
magnification. While this method provided satisfactory results, it required the inoculated agar to
be incubated for a lengthy 8 hours before results could accurately be depicted. To decrease the
amount of time required to establish antibiotic susceptibility profiles, a higher imaging
magnification is recommended. Viewing the bacterial sample at the cell-level will enable
observers to document frequencies of binary fission in as little as 20 minutes (the generation
time of E. coli) per cell. The absence of growth in any allotted timespan indicates effective
inhibition of a concentration of antibiotic. Light microscopy images were taken at 20x
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magnification with similar results (Figure 19), but the resultant field-of-view was too small to
image both the zone of inhibition and overgrowth boundaries. We conclude that light microscopy
is not an efficacious imaging method when considering rapid AST systems. Thus, it is highly
recommended that researchers utilize a low-cost lensless galvo speckle-scanning system,
which was originally intended (Figure 20). While our device is capable of achieving low-cost
antibiotic susceptibility testing, it is currently limited by the time required to incubate and image
the growth of bacterial populations.

Figure 20: Wide-field, high-resolution lensless speckle-scanning system created using nearfield blind ptychographic modulation [19]

Social, Economic, Political, and Cultural Concerns
The results of our project would ultimately reduce the economic toll on healthcare as a
result of multidrug-resistant pathogens. Antibiotic resistance poses a huge threat to the
economy as more and more people become resistant to doses and prescriptions that have
otherwise efficiently treated the prognosis in the past. Specifically, if a patient is resisting usual
antibiotic treatment and needs another prescription, their length of hospital stay will increase
and the previous treatment will have been a wasted expense. Our project will work to determine
the specific antibiotic and concentration that will treat the infection in as little time as possible,
thus reducing the possibility of recurrent hospital visits due to inefficacious treatments. The
speed of this device will allow a decrease in hospital time and cut out the incorrect prescription
stage. This device will serve as an inexpensive alternative to costly antibiotic susceptibility
testing assays and ultimately reduce the burden on both hospital staff and its patients through
rapid and effective treatment protocols. It will also eliminate the need to prescribe expensive
last-line antibiotics as a result of improper initial treatment.
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Environmentally, the greatest cause of resistance comes from the return of antibiotics to
nature. This occurs when antibiotics are discarded as waste or excreted as feces by way of
sewage or landfill, which then leads to the growth of resistant bacteria. Our project seeks to
decrease the amount of waste by making prescriptions more efficient and scarce. By reducing
either the dosage or type of antibiotic being ingested, the effect of the environment can be
slightly improved.
The project will have a high societal impact on how ordinary individuals are diagnosed
and treated. The ultimate aim of this project is to reduce the morbidity of bacterial infections and
thus reduce the burden and potential of disease in society. In theory, instead of attending a
minute clinic for an infection and receiving a basic prescription for the presumed prognosis, a
more specific dosage and antibiotic can be identified. For the ordinary person, this can decrease
the time spent trying to get over an infection that is impacting their everyday life. This, of course,
is the end goal, and will more readily be used to identify the effectiveness of an antibiotic for
more exotic infections vs. the everyday.
Traditional antibiotic susceptibility testing platforms standardized, patented, and massproduced. As a result, simple tests such as the broth microdilution and ETest may cost upwards
of $5 per test (well/strip) for a single antibiotic. Novel rapid AST platforms are capable of
reducing the time required to prescribe effective treatment but often require specialized
machinery and equipment that can well exceed several thousand USD. Our device would
compete in the global market for antibiotic susceptibility tests and imaging devices at a fraction
of the cost of traditional platforms and systems. As a result, it would be suited for all economies
regardless of affluence. Religions or cultures that are not accepted of blood sampling would
likely reject this device. However, our device may be extrapolated to utilize other biological
samples, such as mucous or feces.
Our device does not collect any confidential information or data other than the antibiotic
susceptibility profiles of a patient. Collected information is limited to data protected under HIPAA
regulations, often used to label and track clinical samples. The testing protocol is simple and
minimally invasive. All that is required to conduct rapid AST is a clinical sample, taken from
either the blood or mucous. We aim for beneficence and nonmaleficence by prescribing the
most efficacious treatment possible and preventing the need for recurrent hospitalizations due
to improper treatment.
Our project aims to develop a new antibiotic susceptibility testing platform to significantly
decrease the waiting time for results. Current methods on the market can take anywhere from
12-36 hours to yield results, whereas our product delivers in 1-2 hours. The
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the survival rate of an individual patient decreases by 7.6% with every hour that passes so it is
critical that the testing is completed as quickly as possible. This will have a tremendous impact
on the health and personal safety of people worldwide as antibiotic resistance takes hundreds of
thousands of lives every year.
Our design is easily manufactured at a low cost. The mold is 3D printed from PLA fibers,
which are very affordable. The device itself is made from PDMS, a widely available silicon with a
high curing rate. This antibiotic susceptibility testing system also incorporates a low-cost
lensless galvo speckle-scanning device. This imaging system comes at a fraction of the cost of
traditional light microscopes and provides greater resolution and magnification. The design is
straightforward and could be easily reproduced for clinical use.
The mold of the device takes sustainability efforts into account as it is printed using
organic, renewable material and it can be reused to fabricate several PDMS devices. PLA can
decompose and degrades into non-harmful byproducts. However, the PDMS device is
single-use and must be disposed of after testing. Thus, it is recommended that the mold be
manufactured out of metal and the device be cast out of reusable acrylic or glass.
Future Implications
It is recommended that the final optimized mold be manufactured out of metal to further
prevent the issue of air-bubble formation in the cured PDMS device. The utilization of 3D or
resin printers often results in poor resolution limited by filament size. A metal mold may be
smoothed out to prevent any surface discrepancies/irregularities that could house microscopic
air pockets. A stronger vacuum chamber may also be used to remove small air pockets from the
uncured PDMS. Additionally, the current utilization of PDMS results in a flexible but relatively
soft and delicate device structure. As future development of the device should focus on
minimizing the prototype to true microfluidic applications, we recommend that an acrylic device
be used in place of PDMS to improve both transparency and structural integrity.
The proof-of-concept for the microfluidic device was limited to a population of E. coli
tested against an ampicillin solution under laboratory conditions. To help achieve the goal of
rapid AST, we recommend that the bacterial population be a direct clinical blood sample treated
with anticoagulants. This sample may be diluted with brain and heart infusion to support
fastidious bacterial growth, and then filtered using a 0.45μm membrane to isolate bacterial
populations. From there, the filtered bacterial samples may be used to inoculate brain-and-heart
agar, which may then be poured into the device for rapid AST applications. This would minimize
the time required to establish antibiotic susceptibility profiles by eliminating the need to
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centrifuge whole blood, isolate bacterial populations, proliferate (incubate) the bacteria, and
then test their antibiotic susceptibility profiles.
Finally, it is recommended that the antibiotic concentration gradient be established using
a non-porous strip, or on top of a non-porous barrier. The current porous membrane wicks
moisture away from the agar before the concentration gradient can fully establish. This would
ultimately alter the diffusion approximations and result in inaccurate calculations.
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